Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo

Human Gene Therapy Methods

Volumn 24, Issue 2, 2013, Pages 104-116

  Sen, Dwaipayan ^a   Gadkari, Rupali A ^b   Sudha, Govindarajan ^b   Gabriel, Nishanth ^a   Kumar, Yesupatham Sathish ^a   Selot, Ruchita ^a   Samuel, Rekha ^a   Rajalingam, Sumathi ^a   Ramya, V ^a   Nair, Sukesh C ^a   Srinivasan, Narayanaswamy ^b   Srivastava, Alok ^a   Jayandharan, Giridhara R ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CYTOKINE; ENHANCED GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PROTEIN SERINE THREONINE KINASE; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC VARIABILITY; INNATE IMMUNITY; LIVER; MOUSE; MUTAGENESIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; SEROTYPE; STRUCTURE ACTIVITY RELATION; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CYTOKINES; DEPENDOVIRUS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; HEPATOCYTES; HUMANS; LIVER; LYSINE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SERINE; THREONINE; TRANSDUCTION, GENETIC; UBIQUITINATION;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE; MUS;

EID: 84878699709     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.195     Document Type: Article

References (60)

1. Aurnhammer, C., Haase, M., Muether, N., et al. (2012). Universal Real-Time PCR for the Detection and Quantification of Adeno-Associated Virus Serotype 2-Derived Inverted Terminal Repeat Sequences. Hum. Gene Ther. 23, 18-28.
2. Bowles, D.E., Mcphee, S.W., Li, C., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443-455.
3. Breous, E., Somanathan, S., and Wilson, J.M. (2010). BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol. Ther. 18, 766-774.
4. Calcedo, R., Vandenberghe, L.H., Gao, G., et al. (2009).Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381-390.
5. Chen, J., Wu, Q., Yang, P., et al. (2006). Determination of specific CD4 and CD8 T cell epitopes after AAV2-and AAV8-hF.IX gene therapy. Mol. Ther. 13, 260-269.
6. Chen, J., Liu, H., Yang, J., and Chou, K.C. (2007). Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids 33, 423-428.
7. Choi, V.W., Mccarty, D.M., and Samulski, R.J. (2005). AAV hybrid serotypes: improved vectors for gene delivery. Curr. Gene Ther. 5, 299-310.
8. Davidoff, A.M., Gray, J.T., Ng, C.Y., et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther. 11, 875-888.
9. Delano, W. (2002). The PyMOL molecular graphics system. Available at www.pymol.org/ (accessed May 8, 2012).
10. Deng, W.T., Dinculescu, A., Li, Q., et al. (2012). Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest. Ophthalmol. Vis. Sci. 53, 1895-1904.
11. Erles, K., Sebokova, P., and Schlehofer, J.R. (1999). Update on the prevalence of serum antibodies (IgG and IgM) to adenoassociated virus (AAV). J. Med. Virol. 59, 406-411.
12. Finn, J.D., Hui, D., Downey, H.D., et al. (2010). Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol. Ther. 18, 135-142.
13. Flotte, T.R., and Carter, B.J. (1995). Adeno-associated virus vectors for gene therapy. Gene Ther. 2, 357-362.
14. Gabriel, N., Hareendran, S., Sen, D., et al. (2013). Bioengineering of AAV-2 capsid at specific serine, threonine or lysine residues improves its transduction efficiency in vitro and in vivo. Hum. Gene Ther. Methods. in press.
15. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859.
16. Grimm, D., and Kay, M.A. (2003). From virus evolution to vector revolution: use of naturally occurring serotypes of adenoassociated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3, 281-304.
17. Gurda, B.L., Raupp, C., Popa-Wagner, R., et al. (2012). Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8. J. Virol. 86, 7739-7751.
18. High, K.A. (2012). The gene therapy journey for hemophilia: are we there yet? Blood 120, 4482-4487.
19. Holm, L., and Park, J. (2000). DaliLite workbench for protein structure comparison. Bioinformatics 16, 566-567.
20. Hubbard, S.J., and Thornton, J.M. (1993). NACCESS [computer program]. Department of Biochemistry and Molecular Biology, University College, London.
21. HUSSAIN, T., NASREEN, N., LAI, Y., et al. (2008). Innate immune responses in murine pleural mesothelial cells: Toll-like receptor-2 dependent induction of beta-defensin-2 by staphylococcal peptidoglycan. Am. J. Physiol. Lung Cell Mol. Physiol. 295, L461-470.
22. Jayandharan, G.R., Aslanidi, G., Martino, A.T., et al. (2011). Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc. Natl. Acad. Sci. U.S.A. 108, 3743-3748.
23. Karman, J., Gumlaw, N.K., Zhang, J., et al. (2012). Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors. PLoS One 7, e34684.
24. Kube, D.M., and Srivastava, A. (1997). Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions. Nucleic Acids Res. 25, 3375-3376.
25. Larsen, J.E., Lund, O., and Nielsen, M. (2006). Improved method for predicting linear B-cell epitopes. Immunome Res. 2, 2.
26. Li, C., Narkbunnam, N., Samulski, R.J., et al. (2012). Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 19, 288-294.
27. Liu, Y., Joo, K.I., and Wang, P. (2012). Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther. gt.2012.41
28. Manno, C.S., Pierce, G.F., Arruda, V.R., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
29. Martino, A.T., Suzuki, M., Markusic, D.M., et al. (2011). The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117, 6459-6468.
30. Michou, A.I., Santoro, L., Christ, M., et al. (1997). Adenovirusmediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4, 473-482.
31. Mount, J.D., Herzog, R.W., Tillson, D.M., et al. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99, 2670-2676.
32. Mueller, C., and Flotte, T.R. (2008). Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15, 858-863.
33. Nakai, H., Thomas, C.E., Storm, T.A., et al. (2002). A limited number of transducible hepatocytes restricts a widerange linear vector dose response in recombinant adenoassociated virus-mediated liver transduction. J. Virol. 76, 11343-11349.
34. Nakai, H., Fuess, S., Storm, T.A., et al. (2005). Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79, 214-224.
35. Nam, H.J., Lane, M.D., Padron, E., et al. (2007). Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81, 12260-12271.
36. Nathwani, A.C., Davidoff, A., Hanawa, H., et al. (2001). Factors influencing in vivo transduction by recombinant adenoassociated viral vectors expressing the human factor IX cDNA. Blood 97, 1258-1265.
37. Nathwani, A.C., Davidoff, A.M., Hanawa, H., et al. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100, 1662-1669.
38. Nathwani, A.C., Gray, J.T., Ng, C.Y., et al. (2006). Selfcomplementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107, 2653-2661.
39. Nathwani, A.C., Gray, J.T., Mcintosh, J., et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109, 1414-1421.
40. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
41. Pacak, C.A., and Byrne, B.J. (2011). AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol. Ther. 19, 1582-1590.
42. Petrs-Silva, H., Dinculescu, A., Li, Q., et al. (2011). Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19, 293-301.
43. Qiao, C., Yuan, Z., Li, J., et al. (2012). Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum. Gene Ther. Methods 23, 29-37.
44. Rajkumar, S.V., Richardson, P.G., Hideshima, T., and Anderson, K.C. (2005). Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630-639.
45. Sabatino, D.E., Mingozzi, F., Hui, D.J., et al. (2005). Identification of mouse AAV capsid-specific CD8 + T cell epitopes. Mol. Ther. 12, 1023-1033.
46. Saha, S., and Raghava, G.P. (2006). Prediction of continuous Bcell epitopes in an antigen using recurrent neural network. Proteins 65, 40-48.
47. Schultz, B.R., and Chamberlain, J.S. (2008). Recombinant adenoassociated virus transduction and integration. Mol. Ther. 16, 1189-1199.
48. Snyder, R.O., Miao, C.H., Patijn, G.A., et al. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276.
49. Snyder, R.O., Miao, C., Meuse, L., et al. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5, 64-70.
50. Thomas, C.E., Storm, T.A., Huang, Z., and Kay, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110-3122.
51. Vandenberghe, L.H., Wang, L., Somanathan, S., et al. (2006). Heparin binding directs activation of T cells against adenoassociated virus serotype 2 capsid. Nat. Med. 12, 967-971.
52. Villen, J., Beausoleil, S.A., Gerber, S.A., and Gygi, S.P. (2007). Large-scale phosphorylation analysis of mouse liver. Proc. Natl. Acad. Sci. U.S.A. 104, 1488-1493.
53. Wang, L., Takabe, K., Bidlingmaier, S.M., et al. (1999). Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc. Natl. Acad. Sci. U.S.A. 96, 3906-3910.
54. Wang, Z., Zhu, T., Qiao, C., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328.
55. Wobus, C.E., Hugle-Dorr, B., Girod, A., et al. (2000). Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281-9293.
56. Wu, Z., Asokan, A., and Samulski, R.J. (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316-327.
57. Yan, Z., Zak, R., Luxton, G.W., et al. (2002). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76, 2043-2053.
58. Zhong, L., Li, B., Jayandharan, G., et al. (2008). Tyrosinephosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194-202.
59. Zincarelli, C., Soltys, S., Rengo, G., et al. (2010). Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin. Transl. Sci. 3, 81-89.
60. Zolotukhin, S., Byrne, B.J., Mason, E., et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985.